Patients with prurigo nodularis (PN) have multiple itchy nodules, impaired quality of life, and sleep deprivation. PN patients have a high burden of disease, primarily due to the intensity of the itch. It is reasonable to expect that rapid relief of itch – and associated improvement of sleep – are highly valued clinical outcomes for patients. Nemolizumab is an IL-31A-receptor inhibitor that modulates the neuroimmune response with reported positive efficacy and safety data in a phase 2 study of PN METHODS: Post-hoc analysis of a phase 2 trial of nemolizumab 0.5 mg/kg SC versus placebo in patients (n=70) with moderate to severe PN (≥20 nodules) and severe pruritus (NRS ≥ 7). Time to significant reduction was assessed for pruritus and sleep disturbance (SD), also assessed was scratching time during sleep.